- This topic has 0 replies, 1 voice, and was last updated 8 years ago by
.
Viewing 1 post (of 1 total)
-
Bristol-Myers Squibb appear to be putting some focus on the anti-fibrosis field including investing in licencing rights for development of a promising new drug/delivery system (ND-L02-s0201) that targets HCV and Nash fibrosis.
https://hepatitiscnewdrugs.blogspot.com.au/2016/11/bristol-myers-squibb-signs-exclusive.html
http://liverlearning.aasld.org/aasld/2015/thelivermeeting/110677/%5B%5B$item.link
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Viewing 1 post (of 1 total)
- You must be logged in to reply to this topic.